Tasigna 150mg. 200mg Capsule
PDF Leaflet Revision Date: 30 June 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) in chronic phase.
Dosage (summary)
300 mg twice daily for newly diagnosed Ph+ CML; 400 mg twice daily for resistant/intolerant Ph+ CML.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; potential fetal harm.
Key Drug Interactions
- Avoid strong CYP3A4 inhibitors/inducers
- QT prolonging agents
Contraindications
- Hypersensitivity to nilotinib
Common side effects
- Rash
- Nausea
- Fatigue
- Headache
- Myelosuppression
Counselling Points
- Take on an empty stomach
- Monitor blood glucose and lipids
- Report any signs of cardiovascular issues
Serious warnings
- QT prolongation
- Cardiovascular events
- Hepatitis B reactivation
Important Disclaimer
The Tasigna 150mg. 200mg Capsule professional information leaflet below is the property of Novartis and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
